A. Desai

发表

Use of a claims database to characterize and estimate the incidence rate for Castleman disease

N. Munshi, H. van de Velde, M. Mehra, 2015, Leukemia & lymphoma.

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

D. Esseltine, K. Anderson, P. Sonneveld, 2017, British journal of haematology.

A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.

R. Herbst, D. Carbone, S. Solomon, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.

M. Mehra, A. Desai, R. Potluri, 2016, The oncologist.

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.

D. Esseltine, H. Goldschmidt, P. Sonneveld, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

D. Esseltine, A. Palumbo, P. Richardson, 2014, Haematologica.

High Rates of Transplantation in the Phase III Sierra Trial Utilizing Anti-CD45 (Iodine) 131I-Apamistamab (Iomab-B) Conditioning with Successful Engraftment and Tolerability in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) Patients after Lack of Response to Conventional Care and Targeted Th

M. Berger, P. Hari, K. van Besien, 2022, Transplantation and Cellular Therapy.

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

M. Berger, P. Hari, J. Pagel, 2021, Blood.

Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)

D. Esseltine, P. Sonneveld, S. Lonial, 2013 .

Use of a Claims Database to Characterize and Estimate the Incidence of Castleman's Disease

N. Munshi, M. Mehra, A. Desai, 2012 .

Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features

A. Desai, A. Harrington, M. Hamadani, 2022, Blood.

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

D. Esseltine, A. Palumbo, P. Richardson, 2014, Haematologica.